tiprankstipranks
Trending News
More News >

Philogen S.p.A. Achieves Record Profits and Advances Cancer Therapy Pipeline

Story Highlights
Philogen S.p.A. Achieves Record Profits and Advances Cancer Therapy Pipeline

Confident Investing Starts Here:

An announcement from Philogen SpA ( (IT:PHIL) ) is now available.

Philogen S.p.A. reported a significant financial turnaround in 2024, achieving record profits with revenues tripling from the previous year. The company is advancing its product pipeline with key developments including the ongoing evaluation of Nidlegy™ for melanoma by EMA, promising results in radiopharmaceuticals, and a new collaboration with Sun Pharma for Fibromun. These advancements underscore Philogen’s strengthened position in the biotechnology sector and its commitment to innovative cancer treatments.

More about Philogen SpA

Philogen S.p.A. is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company is involved in research and development, with a market focus on cancer immunotherapy and radiopharmaceuticals.

YTD Price Performance: -2.11%

Average Trading Volume: 290

Technical Sentiment Signal: Sell

Current Market Cap: €580.5M

For a thorough assessment of PHIL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App